---
document_datetime: 2025-10-24 13:48:36
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/columvi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: columvi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 2.9807352
conversion_datetime: 2025-12-27 21:11:12.216044
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Columvi

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary         |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------|
| II/0010              | Submission of the updated 2-year follow-up report from study NP30179 listed as a Specific Obligation in the Annex II of the Product Information. This is a multicenter, open-label Phase I/II study to evaluate the safety, efficacy, tolerability, and pharmacokinetics of escalating doses of glofitamab in | 27/02/2025                          | 08/05/2025                                  | Annex II                         | Not applicable. |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                  | patients with relapsed/refractory B-cell Non- Hodgkin's Lymphoma (NHL). The Annex II is updated accordingly. Consequently, the MAH proposes a switch from conditional marketing authorisation to full marketing authorisation. An editorial update in section 5.1 of the SmPC is made as the statement on CMA is removed. The PL is updated accordingly. The RMP version 5.0 was submitted. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required   |            |            |                                  |                                                                                    |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------|
| PSUSA/67/20 2409 | Periodic Safety Update EU Single assessment - glofitamab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 10/04/2025 | n/a        |                                  | PRAC Recommendation - maintenance                                                  |
| II/0005          | Extension of indication to include in combination with gemcitabine and oxaliplatin the treatment of adult patients with relapse or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are ineligible for autologous stem cell transplant (ASCT) for COLUMVI, based on results of primary and updated analyses from study GO41944 (STARGLO) listed as a Specific Obligation in the Annex II of the Product Information, as well supportive data from the Phase Ib study GO41943. Study GO41944 (STARGLO) is a Phase III, open- label, multicenter, randomised study of glofitamab in combination with GemOx (Glofit-GemOx) vs.                                  | 27/02/2025 | 10/04/2025 | SmPC, Annex II, Labelling and PL | Please refer to Scientific Discussion 'Product Name-H-C- Product Number-II-Var.No' |

<div style=\"page-break-after: always\"></div>

|         | rituximab in combination with GemOx (R-GemOx) in patients with R/R DLBCL. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Annex II and Package Leaflet are updated in accordance. Version 2.2 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and update the list of local representatives in the Package Leaflet. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one   |            |            |                       |           |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-----------|
| IB/0009 | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                 | 09/01/2025 | n/a        |                       |           |
| IB/0008 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 11/12/2024 | 10/04/2025 | SmPC, Annex II and PL |           |
|         | This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting                                                                                                                        | 07/11/2024 | n/a        |                       | II/0006/G |

<div style=\"page-break-after: always\"></div>

| material/intermediate B.II.b.1.c - Replacement manufacturing site for manufacturing operation(s) release/control, and secondary biol/immunol medicinal forms manufactured by processes B.I.a.2.b - Changes in the AS - Substantial change process of the AS which impact on the quality, medicinal product B.II.d.2.a - Change in product - Minor changes procedure A.7 - Administrative change manufacturing sites B.II.d.2.d - Change in product - Other changes (including replacement B.II.f.1.e - Stability of stability protocol B.I.b.1.b - Change in the and/or limits of an AS, material/intermediate/reagent specification limits B.I.b.2.a - Change in test starting material/reagent/intermediate   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| PSUSA/67/20 2403   | Periodic Safety Update EU Single assessment - glofitamab                                                                                                                            | 31/10/2024   | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0003             | Renewal of the marketing authorisation.                                                                                                                                             | 21/03/2024   | 27/05/2024 |             | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Columvi, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |
| PSUSA/67/20 2309   | Periodic Safety Update EU Single assessment - glofitamab                                                                                                                            | 11/04/2024   | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IB/0001            | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol | 03/01/2024   | 27/05/2024 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |